首页>
外国专利>
Pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride
Pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride
展开▼
机译：包含糠酸莫米松和盐酸氮卓斯汀的鼻腔给药药物组合物
展开▼
页面导航
摘要
著录项
相似文献
摘要
PURPOSE: A pharmaceutical composition containing mometasone furoate, azelastine hydrochloride, and thaumatin is provided to enhance drug compliance. CONSTITUTION: A pharmaceutical composition for endonasal adminisration contains 0.01-1.0 w/v% of mometasone furoate and 0.05-1.0 w/v% of azelastine hydrochloride. The pharmaceutical composition also contains 0.1-0.5 w/v% of thaumatin as an agent for relieving bitter taste and stimulation. The pharmaceutical composition further contains 1.0-5.0 w/v% of tackifier, 0.2-0.6 w/v% of buffer, 0.001-0.1 w/v% of surfactant, 5.0-10.0 w/v% of isotonic agent, 0.01-1.0 w/v% of stabilizing agent, and 0.002-0.05 w/v% of preservative in an aqueous medium. The pharmaceutical composition for endonasal administration is formulated in a nasal spray.
展开▼
机译：目的：提供一种药物组合物，其中含有糠酸莫米松，盐酸氮卓斯汀和奇异果甜蛋白，以增强药物的依从性。组成：用于鼻内给药的药物组合物包含0.01-1.0 w / v％的糠酸莫米松和0.05-1.0 w / v％的盐酸氮卓斯汀。该药物组合物还包含0.1-0.5 w / v％的奇异果甜蛋白作为减轻苦味和刺激的试剂。该药物组合物还包含1.0-5.0 w / v％的增粘剂，0.2-0.6 w / v％的缓冲剂，0.001-0.1 w / v％的表面活性剂，5.0-10.0 w / v％的等渗剂，0.01-1.0 w / v％的稳定剂和0.002-0.05 w / v％的防腐剂在水性介质中。用于鼻内给药的药物组合物被配制成鼻喷雾剂。
展开▼
